Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 148

1.

Combined use of genetic polymorphisms and elastographic techniques in NAFLD. Fact or fiction?

Lombardi R, Fargion S, Fracanzani AL.

Curr Pharm Des. 2019 Nov 21. doi: 10.2174/1381612825666191122101021. [Epub ahead of print]

PMID:
31755380
2.

Impact of natural Neuromedin-B receptor variants on iron metabolism.

Rametta R, Dongiovanni P, Baselli GA, Pelusi S, Meroni M, Fracanzani AL, Busti F, Castagna A, Scarlini S, Corradini E, Pietrangelo A, Girelli D, Fargion S, Valenti L.

Am J Hematol. 2019 Nov 14. doi: 10.1002/ajh.25679. [Epub ahead of print]

PMID:
31724192
3.

mir-101-3p Downregulation Promotes Fibrogenesis by Facilitating Hepatic Stellate Cell Transdifferentiation During Insulin Resistance.

Meroni M, Longo M, Erconi V, Valenti L, Gatti S, Fracanzani AL, Dongiovanni P.

Nutrients. 2019 Oct 29;11(11). pii: E2597. doi: 10.3390/nu11112597.

4.

β-Klotho gene variation is associated with liver damage in children with NAFLD.

Dongiovanni P, Crudele A, Panera N, Romito I, Meroni M, De Stefanis C, Palma A, Comparcola D, Fracanzani AL, Miele L, Valenti L, Nobili V, Alisi A.

J Hepatol. 2019 Oct 23. pii: S0168-8278(19)30613-0. doi: 10.1016/j.jhep.2019.10.011. [Epub ahead of print]

5.

Liver fibrosis by FibroScan® independently of established cardiovascular risk parameters associates with macrovascular and microvascular complications in patients with type 2 diabetes.

Lombardi R, Airaghi L, Targher G, Serviddio G, Maffi G, Mantovani A, Maffeis C, Colecchia A, Villani R, Rinaldi L, Orsi E, Pisano G, Adinolfi LE, Fargion S, Fracanzani AL.

Liver Int. 2019 Oct 14. doi: 10.1111/liv.14274. [Epub ahead of print]

PMID:
31612634
6.

High prevalence of early atherosclerotic and cardiac damage in patients undergoing liver transplantation: Preliminary results.

Pisano G, Donato MF, Consonni D, Oberti G, Borroni V, Lombardi R, Invernizzi F, Bertelli C, Caccamo L, Porzio M, Dondossola D, Rossi G, Fargion S, Fracanzani AL.

Dig Liver Dis. 2019 Sep 11. pii: S1590-8658(19)30709-1. doi: 10.1016/j.dld.2019.07.007. [Epub ahead of print]

PMID:
31521545
7.

Lipid accumulation impairs lysosomal acid lipase activity in hepatocytes: Evidence in NAFLD patients and cell cultures.

Gomaraschi M, Fracanzani AL, Dongiovanni P, Pavanello C, Giorgio E, Da Dalt L, Norata GD, Calabresi L, Consonni D, Lombardi R, Branchi A, Fargion S.

Biochim Biophys Acta Mol Cell Biol Lipids. 2019 Dec;1864(12):158523. doi: 10.1016/j.bbalip.2019.158523. Epub 2019 Sep 7.

PMID:
31505261
8.

Procoagulant imbalance influences cardiovascular and liver damage in chronic hepatitis C independently of steatosis.

Sigon G, D'Ambrosio R, Clerici M, Pisano G, Chantarangkul V, Sollazzi R, Lombardi R, Peyvandi F, Lampertico P, Fargion S, Tripodi A, Fracanzani AL.

Liver Int. 2019 Dec;39(12):2309-2316. doi: 10.1111/liv.14213. Epub 2019 Aug 30.

PMID:
31419372
9.

Brain involvement in non-alcoholic fatty liver disease (NAFLD): A systematic review.

Lombardi R, Fargion S, Fracanzani AL.

Dig Liver Dis. 2019 Sep;51(9):1214-1222. doi: 10.1016/j.dld.2019.05.015. Epub 2019 Jun 6.

PMID:
31176631
10.

Impact of Obesity and Alanine Aminotransferase Levels on the Diagnostic Accuracy for Advanced Liver Fibrosis of Noninvasive Tools in Patients With Nonalcoholic Fatty Liver Disease.

Petta S, Wai-Sun Wong V, Bugianesi E, Fracanzani AL, Cammà C, Hiriart JB, Lai-Hung Wong G, Vergniol J, Wing-Hung Chan A, Giannetti A, Merrouche W, Lik-Yuen Chan H, Le-Bail B, Lombardi R, Guastella S, Craxì A, de Ledinghen V.

Am J Gastroenterol. 2019 Jun;114(6):916-928. doi: 10.14309/ajg.0000000000000153.

PMID:
31169533
11.

PCSK7 gene variation bridges atherogenic dyslipidemia with hepatic inflammation in NAFLD patients.

Dongiovanni P, Meroni M, Baselli G, Mancina RM, Ruscica M, Longo M, Rametta R, Cespiati A, Pelusi S, Ferri N, Ranzani V, Nobili V, Pihlajamaki J, Fracanzani AL, Badiali S, Petta S, Fargion S, Romeo S, Kozlitina J, Valenti L.

J Lipid Res. 2019 Jun;60(6):1144-1153. doi: 10.1194/jlr.P090449. Epub 2019 Mar 27.

PMID:
30918065
12.

Rare Pathogenic Variants Predispose to Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease.

Pelusi S, Baselli G, Pietrelli A, Dongiovanni P, Donati B, McCain MV, Meroni M, Fracanzani AL, Romagnoli R, Petta S, Grieco A, Miele L, Soardo G, Bugianesi E, Fargion S, Aghemo A, D'Ambrosio R, Xing C, Romeo S, De Francesco R, Reeves HL, Valenti LVC.

Sci Rep. 2019 Mar 6;9(1):3682. doi: 10.1038/s41598-019-39998-2.

13.

Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis.

Pelusi S, Cespiati A, Rametta R, Pennisi G, Mannisto V, Rosso C, Baselli G, Dongiovanni P, Fracanzani AL, Badiali S, Maggioni M, Craxi A, Fargion S, Prati D, Nobili V, Bugianesi E, Romeo S, Pihlajamaki J, Petta S, Valenti L.

Clin Gastroenterol Hepatol. 2019 Oct;17(11):2310-2319.e6. doi: 10.1016/j.cgh.2019.01.027. Epub 2019 Jan 29.

PMID:
30708111
14.

Evaluation of three "beyond Baveno VI" criteria to safely spare endoscopies in compensated advanced chronic liver disease.

Tosetti G, Primignani M, La Mura V, D'Ambrosio R, Degasperi E, Mezzina N, Viganò M, Rumi M, Fracanzani AL, Lombardi R, Fargion S, Fraquelli M, Aghemo A, Lampertico P.

Dig Liver Dis. 2019 Aug;51(8):1135-1140. doi: 10.1016/j.dld.2018.12.025. Epub 2019 Jan 11.

PMID:
30691777
15.

miRNA Signature in NAFLD: A Turning Point for a Non-Invasive Diagnosis.

Dongiovanni P, Meroni M, Longo M, Fargion S, Fracanzani AL.

Int J Mol Sci. 2018 Dec 10;19(12). pii: E3966. doi: 10.3390/ijms19123966. Review.

16.

FibroScan Detects Cardiovascular Damage in Patients With NAFLD.

Lombardi R, Petta S, Pisano G, Dongiovanni P, Rinaldi L, Adinolfi LE, Acierno C, Valenti L, Boemi R, Spatola F, Craxì A, Fargion S, Fracanzani AL.

Clin Gastroenterol Hepatol. 2018 Dec 8. pii: S1542-3565(18)31254-0. doi: 10.1016/j.cgh.2018.11.011. [Epub ahead of print]

PMID:
30528844
17.

A sweet fever.

Tiraboschi S, Marzano AV, Lombardi R, Genovese G, Boccoli G, Fargion S, Fracanzani AL.

Intern Emerg Med. 2019 Oct;14(7):1125-1128. doi: 10.1007/s11739-018-1975-y. Epub 2018 Nov 8. No abstract available.

PMID:
30406876
18.

Progressive splenomegaly and mild thrombocytosis in beta-thalassaemia trait and coexisting hereditary hemochromatosis: possible confounders for a subsequent hematological diagnosis.

Pelusi S, Iuculano F, Lombardi R, Francione P, Gianelli U, Fracanzani AL, Fargion S.

Intern Emerg Med. 2019 Aug;14(5):763-766. doi: 10.1007/s11739-018-1947-2. Epub 2018 Sep 14. No abstract available.

PMID:
30218421
19.

Protein phosphatase 1 regulatory subunit 3B gene variation protects against hepatic fat accumulation and fibrosis in individuals at high risk of nonalcoholic fatty liver disease.

Dongiovanni P, Meroni M, Mancina RM, Baselli G, Rametta R, Pelusi S, Männistö V, Fracanzani AL, Badiali S, Miele L, Grimaudo S, Petta S, Bugianesi E, Soardo G, Fargion S, Pihlajamäki J, Romeo S, Valenti L.

Hepatol Commun. 2018 Apr 25;2(6):666-675. doi: 10.1002/hep4.1192. eCollection 2018 Jun.

20.

Non-invasive prediction of esophageal varices by stiffness and platelet in non-alcoholic fatty liver disease cirrhosis.

Petta S, Sebastiani G, Bugianesi E, Viganò M, Wong VW, Berzigotti A, Fracanzani AL, Anstee QM, Marra F, Barbara M, Calvaruso V, Cammà C, Di Marco V, Craxì A, de Ledinghen V.

J Hepatol. 2018 Oct;69(4):878-885. doi: 10.1016/j.jhep.2018.05.019. Epub 2018 May 24.

PMID:
29802949
21.

Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis.

Petta S, Adinolfi LE, Fracanzani AL, Rini F, Caldarella R, Calvaruso V, Cammà C, Ciaccio M, Di Marco V, Grimaudo S, Licata A, Marrone A, Nevola R, Pipitone RM, Pinto A, Rinaldi L, Torres D, Tuttolomondo A, Valenti L, Fargion S, Craxì A.

J Hepatol. 2018 Jul;69(1):18-24. doi: 10.1016/j.jhep.2018.02.015. Epub 2018 Mar 2.

PMID:
29505844
22.

Subclinical cerebrovascular disease in NAFLD without overt risk factors for atherosclerosis.

Airaghi L, Rango M, Maira D, Barbieri V, Valenti L, Lombardi R, Biondetti P, Fargion S, Fracanzani AL.

Atherosclerosis. 2018 Jan;268:27-31. doi: 10.1016/j.atherosclerosis.2017.11.012. Epub 2017 Nov 16.

PMID:
29175651
23.

Harmful and Beneficial Effects of Anticoagulants in Patients With Cirrhosis and Portal Vein Thrombosis.

La Mura V, Braham S, Tosetti G, Branchi F, Bitto N, Moia M, Fracanzani AL, Colombo M, Tripodi A, Primignani M.

Clin Gastroenterol Hepatol. 2018 Jul;16(7):1146-1152.e4. doi: 10.1016/j.cgh.2017.10.016. Epub 2017 Oct 21.

PMID:
29066371
24.

Acquired hepatocerebral degeneration (AHD): a peculiar neurological impairment in advanced chronic liver disease.

Pigoni A, Iuculano F, Saetti C, Airaghi L, Burdick L, Spreafico S, Curioni M, Lombardi R, Valenti L, Fracanzani AL, Fargion S.

Metab Brain Dis. 2018 Feb;33(1):347-352. doi: 10.1007/s11011-017-0107-0. Epub 2017 Sep 16.

PMID:
28918510
25.

PCSK9 deficiency results in increased ectopic fat accumulation in experimental models and in humans.

Baragetti A, Balzarotti G, Grigore L, Pellegatta F, Guerrini U, Pisano G, Fracanzani AL, Fargion S, Norata GD, Catapano AL.

Eur J Prev Cardiol. 2017 Nov;24(17):1870-1877. doi: 10.1177/2047487317724342. Epub 2017 Jul 31.

PMID:
28758421
26.

Interferon lambda 4 rs368234815 TT>δG variant is associated with liver damage in patients with nonalcoholic fatty liver disease.

Petta S, Valenti L, Tuttolomondo A, Dongiovanni P, Pipitone RM, Cammà C, Cabibi D, Di Marco V, Fracanzani AL, Badiali S, Nobili V, Fargion S, Grimaudo S, Craxì A.

Hepatology. 2017 Dec;66(6):1885-1893. doi: 10.1002/hep.29395. Epub 2017 Nov 6.

PMID:
28741298
27.

Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease.

Donati B, Pietrelli A, Pingitore P, Dongiovanni P, Caddeo A, Walker L, Baselli G, Pelusi S, Rosso C, Vanni E, Daly A, Mancina RM, Grieco A, Miele L, Grimaudo S, Craxi A, Petta S, De Luca L, Maier S, Soardo G, Bugianesi E, Colli F, Romagnoli R, Anstee QM, Reeves HL, Fracanzani AL, Fargion S, Romeo S, Valenti L.

Cancer Med. 2017 Aug;6(8):1930-1940. doi: 10.1002/cam4.1078. Epub 2017 Jul 4.

28.

MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals.

Donati B, Dongiovanni P, Romeo S, Meroni M, McCain M, Miele L, Petta S, Maier S, Rosso C, De Luca L, Vanni E, Grimaudo S, Romagnoli R, Colli F, Ferri F, Mancina RM, Iruzubieta P, Craxi A, Fracanzani AL, Grieco A, Corradini SG, Aghemo A, Colombo M, Soardo G, Bugianesi E, Reeves H, Anstee QM, Fargion S, Valenti L.

Sci Rep. 2017 Jul 3;7(1):4492. doi: 10.1038/s41598-017-04991-0.

29.

Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.

Fracanzani AL, Petta S, Lombardi R, Pisano G, Russello M, Consonni D, Di Marco V, Cammà C, Mensi L, Dongiovanni P, Valenti L, Craxì A, Fargion S.

Clin Gastroenterol Hepatol. 2017 Oct;15(10):1604-1611.e1. doi: 10.1016/j.cgh.2017.04.045. Epub 2017 May 26.

PMID:
28554682
30.

Fibronectin Type III Domain-Containing Protein 5 rs3480 A>G Polymorphism, Irisin, and Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.

Petta S, Valenti L, Svegliati-Baroni G, Ruscica M, Pipitone RM, Dongiovanni P, Rychlicki C, Ferri N, Cammà C, Fracanzani AL, Pierantonelli I, Di Marco V, Meroni M, Giordano D, Grimaudo S, Maggioni M, Cabibi D, Fargion S, Craxì A.

J Clin Endocrinol Metab. 2017 Aug 1;102(8):2660-2669. doi: 10.1210/jc.2017-00056.

PMID:
28472477
31.

Severe reduction of blood lysosomal acid lipase activity in cryptogenic cirrhosis: A nationwide multicentre cohort study.

Angelico F, Corradini SG, Pastori D, Fargion S, Fracanzani AL, Angelico M, Bolondi L, Tozzi G, Pujatti PL, Labbadia G, Corazza GR, Averna M, Perticone F, Croce G, Persico M, Bucci T, Baratta F, Polimeni L, Del Ben M, Violi F; LAL-Cirrhosis Collaborative Research Group.

Atherosclerosis. 2017 Jul;262:179-184. doi: 10.1016/j.atherosclerosis.2017.03.038. Epub 2017 Mar 31.

PMID:
28396038
32.

Cardiovascular risk after orthotopic liver transplantation, a review of the literature and preliminary results of a prospective study.

Pisano G, Fracanzani AL, Caccamo L, Donato MF, Fargion S.

World J Gastroenterol. 2016 Oct 28;22(40):8869-8882. Review.

33.

Procoagulant imbalance in patients with non-alcoholic fatty liver disease.

Tripodi A, Fracanzani AL, Chantarangkul V, Primignani M, Fargion S.

J Hepatol. 2017 Jan;66(1):248-250. doi: 10.1016/j.jhep.2016.09.025. Epub 2016 Oct 18. No abstract available.

PMID:
27769731
34.

Renin-Angiotensin System Inhibitors, Type 2 Diabetes and Fibrosis Progression: An Observational Study in Patients with Nonalcoholic Fatty Liver Disease.

Pelusi S, Petta S, Rosso C, Borroni V, Fracanzani AL, Dongiovanni P, Craxi A, Bugianesi E, Fargion S, Valenti L.

PLoS One. 2016 Sep 20;11(9):e0163069. doi: 10.1371/journal.pone.0163069. eCollection 2016.

35.

Epicardial Adipose Tissue (EAT) Thickness Is Associated with Cardiovascular and Liver Damage in Nonalcoholic Fatty Liver Disease.

Fracanzani AL, Pisano G, Consonni D, Tiraboschi S, Baragetti A, Bertelli C, Norata GD, Dongiovanni P, Valenti L, Grigore L, Tonella T, Catapano A, Fargion S.

PLoS One. 2016 Sep 14;11(9):e0162473. doi: 10.1371/journal.pone.0162473. eCollection 2016.

36.

Liver fat accumulation is associated with circulating PCSK9.

Ruscica M, Ferri N, Macchi C, Meroni M, Lanti C, Ricci C, Maggioni M, Fracanzani AL, Badiali S, Fargion S, Magni P, Valenti L, Dongiovanni P.

Ann Med. 2016 Aug;48(5):384-91. doi: 10.1080/07853890.2016.1188328. Epub 2016 May 25.

PMID:
27222915
37.

Vascular Damage in Patients with Nonalcoholic Fatty Liver Disease: Possible Role of Iron and Ferritin.

Pisano G, Lombardi R, Fracanzani AL.

Int J Mol Sci. 2016 May 5;17(5). pii: E675. doi: 10.3390/ijms17050675. Review.

38.

Progression of carotid vascular damage and cardiovascular events in non-alcoholic fatty liver disease patients compared to the general population during 10 years of follow-up.

Fracanzani AL, Tiraboschi S, Pisano G, Consonni D, Baragetti A, Bertelli C, Norata D, Valenti L, Grigore L, Porzio M, Catapano A, Fargion S.

Atherosclerosis. 2016 Mar;246:208-13. doi: 10.1016/j.atherosclerosis.2016.01.016. Epub 2016 Jan 12.

PMID:
26803429
39.

Subclinical atherosclerosis is associated with Epicardial Fat Thickness and hepatic steatosis in the general population.

Baragetti A, Pisano G, Bertelli C, Garlaschelli K, Grigore L, Fracanzani AL, Fargion S, Norata GD, Catapano AL.

Nutr Metab Cardiovasc Dis. 2016 Feb;26(2):141-53. doi: 10.1016/j.numecd.2015.10.013. Epub 2015 Nov 2.

PMID:
26777475
40.

The rs2294918 E434K variant modulates patatin-like phospholipase domain-containing 3 expression and liver damage.

Donati B, Motta BM, Pingitore P, Meroni M, Pietrelli A, Alisi A, Petta S, Xing C, Dongiovanni P, del Menico B, Rametta R, Mancina RM, Badiali S, Fracanzani AL, Craxì A, Fargion S, Nobili V, Romeo S, Valenti L.

Hepatology. 2016 Mar;63(3):787-98. doi: 10.1002/hep.28370. Epub 2016 Jan 14.

PMID:
26605757
41.

Increased circulating adiponectin in males with chronic HCV hepatitis.

Canavesi E, Porzio M, Ruscica M, Rametta R, Macchi C, Pelusi S, Fracanzani AL, Dongiovanni P, Fargion S, Magni P, Valenti L.

Eur J Intern Med. 2015 Oct;26(8):635-9. doi: 10.1016/j.ejim.2015.08.001. Epub 2015 Aug 17.

PMID:
26293833
42.

Ovarian senescence increases liver fibrosis in humans and zebrafish with steatosis.

Turola E, Petta S, Vanni E, Milosa F, Valenti L, Critelli R, Miele L, Maccio L, Calvaruso V, Fracanzani AL, Bianchini M, Raos N, Bugianesi E, Mercorella S, Di Giovanni M, Craxì A, Fargion S, Grieco A, Cammà C, Cotelli F, Villa E.

Dis Model Mech. 2015 Sep;8(9):1037-46. doi: 10.1242/dmm.019950. Epub 2015 Jul 16.

43.

Transmembrane 6 superfamily member 2 gene E167K variant impacts on steatosis and liver damage in chronic hepatitis C patients.

Milano M, Aghemo A, Mancina RM, Fischer J, Dongiovanni P, De Nicola S, Fracanzani AL, D'Ambrosio R, Maggioni M, De Francesco R, Fargion S, Berg T, Stickel F, Hampe J, Romeo S, Colombo M, Valenti L.

Hepatology. 2015 Jul;62(1):111-7. doi: 10.1002/hep.27811. Epub 2015 May 6.

PMID:
25820484
44.

High fat diet subverts hepatocellular iron uptake determining dysmetabolic iron overload.

Dongiovanni P, Lanti C, Gatti S, Rametta R, Recalcati S, Maggioni M, Fracanzani AL, Riso P, Cairo G, Fargion S, Valenti L.

PLoS One. 2015 Feb 3;10(2):e0116855. doi: 10.1371/journal.pone.0116855. eCollection 2015. Erratum in: PLoS One. 2015;10(3):e0120457.

45.

The UCP2 -866 G>A promoter region polymorphism is associated with nonalcoholic steatohepatitis.

Fares R, Petta S, Lombardi R, Grimaudo S, Dongiovanni P, Pipitone R, Rametta R, Fracanzani AL, Mozzi E, Craxì A, Fargion S, Sesti G, Valenti L.

Liver Int. 2015 May;35(5):1574-80. doi: 10.1111/liv.12707. Epub 2014 Nov 20.

PMID:
25351290
46.

Nonalcoholic fatty liver disease and vascular disease: state-of-the-art.

Fargion S, Porzio M, Fracanzani AL.

World J Gastroenterol. 2014 Oct 7;20(37):13306-24. doi: 10.3748/wjg.v20.i37.13306. Review.

47.

Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease.

Dongiovanni P, Petta S, Maglio C, Fracanzani AL, Pipitone R, Mozzi E, Motta BM, Kaminska D, Rametta R, Grimaudo S, Pelusi S, Montalcini T, Alisi A, Maggioni M, Kärjä V, Borén J, Käkelä P, Di Marco V, Xing C, Nobili V, Dallapiccola B, Craxi A, Pihlajamäki J, Fargion S, Sjöström L, Carlsson LM, Romeo S, Valenti L.

Hepatology. 2015 Feb;61(2):506-14. doi: 10.1002/hep.27490.

PMID:
25251399
48.

Juvenile hemochromatosis associated with heterozygosity for novel hemojuvelin mutations and with unknown cofactors.

Pelusi S, Rametta R, Della Corte C, Congia R, Dongiovanni P, Pulixi EA, Fargion S, Fracanzani AL, Nobili V, Valenti L.

Ann Hepatol. 2014 Sep-Oct;13(5):568-71.

49.

Role of iron in hepatocellular carcinoma.

Fargion S, Valenti L, Fracanzani AL.

Clin Liver Dis (Hoboken). 2014 May 27;3(5):108-110. doi: 10.1002/cld.350. eCollection 2014 May. No abstract available.

50.

Hepatic steatosis and PNPLA3 I148M variant are associated with serum Fetuin-A independently of insulin resistance.

Rametta R, Ruscica M, Dongiovanni P, Macchi C, Fracanzani AL, Steffani L, Fargion S, Magni P, Valenti L.

Eur J Clin Invest. 2014 Jul;44(7):627-33. doi: 10.1111/eci.12280.

PMID:
24828988

Supplemental Content

Loading ...
Support Center